In the modern era of molecular medicine, in which striking advances have become common place, it is easy to forget the remarkable vision of those who, 50 years ago, saw the need to create a dedicated service for people with musculoskeletal disease in the West of Scotland.
In the adverse social climate in Glasgow in the early 1960s, with no designated rheumatology service, rapid disease progression in, for example, rheumatoid arthritis (RA) with resulting disability was frequently seen. Miss Margaret Herbison, MP for North Lanarkshire and Minister of Pensions in Harold Wilson's government, campaigned in Westminster for a Glasgow unit for more than five years -her efforts were finally rewarded when the Centre for Rheumatic Diseases (CRD) opened in 1965. The 1965 Western region publication reports that the cost of refurbishment of the building at 35 Baird Street was £130,000.
Watson Buchanan was the charismatic and energetic senior lecturer in the University of Glasgow appointed to lead the new service.
He and his team established an ethos, which has endured over the ensuing 50 years -a clear ambition to study and understand the complex and fascinating rheumatic disorders, and to improve standards of care for rheumatic disease patients. In many respects, the CRD was a pioneering institution in which clinical excellence and medical innovation came together, driven by curiosity and by a determination to improve patients' lives. Co-operation with laboratory colleagues was a prominent early feature of CRD, with the regional immunology laboratory situated on the top floor of Baird Street.
Late referral and long neglected inflammatory disease meant that management of disability was the main focus of CRD in the early years and orthopaedic input was vital. Surgical requirements were extensive: many patients underwent bilateral hip and knee replacements, and later, as expertise evolved, shoulder, elbow, hand, foot and neck surgery. Fund raising in the fledgling department of rheumatology provided much needed money to enhance services for patients and remained an ongoing theme over five decades.
When Watson emigrated to Canada in 1979, the unit lost an inspiring teacher who had succeeded in conveying his own unquenchable intellectual curiosity and enthusiasm to those privileged to work with him. In 1979, Roger Sturrock was appointed Senior Lecturer and Hilary Capell NHS Consultant in CRD. The unit moved from Baird Street to Glasgow Royal Infirmary in June 1984. There close collaboration with colleagues in other disciplines was valuable in dealing with co-morbidity such as sepsis, gastro intestinal morbidity from non-steroidal anti-inflammatory drugs (NSAIDs) and premature cardiovascular morbidity and mortality.
Controlling inflammation with 'disease modifying agents' became a key aspect and facilitated a significant reduction in NSAID prescription.With only two consultants in CRD throughout the 1960s, 1970s and 1980s, facilities for patients with rheumatological diseases remained far short of the British Society for Rheumatology recommendations. Campaigns to promote the establishment of posts in surrounding areas and prevent long distance travel for patients eventually yielded results, and West Scottish units were established/developed by emissaries from CRD -in West Glasgow (at GGH) in 1977 (Patrick Rooney then John Hunter), Ayr in 1979 (Peter Reynolds), Inverness in 1985 (Malcolm Steven) and Lanarkshire in 1987 (Asad Zoma).
These appointments led to a demonstrable reduction in cross boundary flow and distances patients needed to travel.
Within CRD, in the 1990s, the appointments of Max Field, Rajan Madhok and Iain McInnes, increased staffing to five consultants, and both the capacity and the diversity of the unit were greatly enhanced. Roger Sturrock was appointed the first ARC/McLeod chair of rheumatology in 1990.
Across the years, patients with musculoskeletal diseases were the central focus of investigation of evolving treatment options, and their willingness to co-operate with rheumatology research projects has been remarkable.
Generations of health-care professionals from Scotland, the United Kingdom and beyond have contributed to the high quality of clinical care, training and research. Metrology input to patient evaluation, which had been initiated by Watson Buchanan, was refined, developed and extended. Meticulous study documentation was of course central to their role, but the additional dimension metrologists were able to provide for patient care proved invaluable in the functioning of CRD over the following decades.
Redesign of the clinical service led to increasing emphasis on day and outpatient care along with targeted intra articular corticosteroid injections (latterly under ultra sound guidance where needed).
The establishment of specialist nurse and physiotherapy posts, with space for concomitant day ward services transformed patient care -these specialist practitioners have worked tirelessly to deliver a modern flexible service. This has greatly improved patient care and made inpatient treatment a rarity. Recently, Mhairi Brandon was appointed the unit's first consultant physiotherapist.
In 2008 The unit has subsequently published widely in this field and hosts a trials unit specialising in the use of biologic agents in early inflammatory arthritis. Iain was appointed as director of the Institute of Infection Immunity and Inflammation in the University in 2010, Muirhead Professor of Medicine in 2012 and Arthritis Research Professor of Rheumatology in 2014.
The CRD has contributed towards many strands of practice in the current remarkable changes in the treatment of arthritis, especially since the turn of the century -in the evolution of novel treatment strategies, optimisation of drug management and recognition of the importance of co-morbidities, especially in the vascular system, and this has permitted the development of interventions that have saved many lives over the years.
More recently, as the scope of activities in CRD has grown to embrace the excellent basic science in the University of Glasgow, have come invaluable contributions to knowledge of the underlying pathology of musculoskeletal diseases, especially of RA and the spondyloarthropathies.
Indeed so rapidly has the management of early RA evolved that SIGN guideline 48 published in 2000 was revised in 2004 and then rapidly superceded by guideline 123 published in 2011.
New targets and new biomarkers are emerging and provide promising opportunities for the future. Research into cytokines to target for future therapies has opened new avenues, and as this exciting field has continued to evolve biologic therapies have become more widely available.
Steady progress in the range and efficacy of available therapies over the past 25 years has meant that improvements in outcomes have also been observed in ankylosing spondylitis and juvenile idiopathic arthritis. Patients with systemic sclerosis and systemic lupus erythematosus (SLE) are beginning to show improved outcomes after many years of meticulous work caring for individuals, refining assessments and evaluating therapies for these complex conditions. Partnerships with colleagues in Glasgow Caledonian and Strathclyde Universities have added and continue to supplement CRD research efforts so that they span a truly multidisciplinary spectrum.
The unit has benefited from the generosity of funders in the Research Councils, Government, industry and charitable sectors.
The Scottish government funded several major RA therapy studies from the late 1990s onwards. Following on from these studies, collaborative clinical research in Scotland has taken a step forward with the establishment of the Scottish Collaborative Arthritis Research Network (Clinical lead Duncan Porter in GGH and co-ordinator Ann Tierney in GRI). A Scottish wide database was also set up for Ankylosing Spondylitis (SIRAS) with the department of Epidemiology (Prof. Gary Macfarlane) at the University of Aberdeen. Several studies are in progress under this umbrella, with funding from Arthritis Research UK along with a contribution from the pharmaceutical industry. These multi centre studies allow important clinical questions to be addressed without unrealistic restrictions on enrolment and are hence more relevant to Scottish clinical practice.
Between 1987 and 2014, Arthritis Research UK provided funds totaling £17.5 million for research projects/ fellowships in CRD.
Their most recent investment has been into the RA Pathogenesis Centre of Excellence, a project in conjunction with the Universities of Glasgow (spear headed by Iain McInnes), Birmingham and Newcastle. Part of the £2.5 million funding allows for the recruitment of PhD students and post doctoral researchers who will spend time in at least two of the three partner units, thus enhancing communication between the three university hubs.
This research aims to elucidate mechanisms behind the development of RA, which should in turn lead to more effective treatments in the future. CRD consultants have contributed over five decades to the working groups and committees of Arthritis Research UK, including education, research, clinical trials groups and scientific co-ordinating committees. There has also been a major input into the British Society for Rheumatology and all leading rheumatological journals.
The CRD is proud to be a European League against Rheumatism Centre of Excellence reflecting
